[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-333270-105":59,"doc-detail-333270-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","lncrna-cytor-promotes-lung-adenocarcinoma-gemcitabine-resistance-and-epithelial-mesenchymal-transition","lncRNA CYTOR promotes lung adenocarcinoma gemcitabine resistance and epithelial-mesenchymal transition","","Lung adenocarcinoma (LUAD) remains highly aggressive, with poor prognosis and limited effectiveness of gemcitabine-based chemotherapy. This study evaluates whether lncRNA CYTOR dysregulation contributes to gemcitabine resistance and clinical outcomes in LUAD, using quantitative RT-PCR and Kaplan-Meier survival analyses. CYTOR’s functions are tested through in vitro and in vivo experiments, complemented by mechanistic assays including RNA immunoprecipitation, biotin-labeled RNA pulldown, luciferase reporters, and western blotting. CYTOR is identified as an oncogenic lncRNA upregulated in LUAD, associated with worse survival, promoting stronger gemcitabine resistance and epithelial-mesenchymal transition (EMT). Mechanistically, CYTOR acts as a competitive endogenous RNA that sponges miR-125a-5p, reduces its antitumor activity, and upregulates ANLN and RRM2, outlining a framework for further LUAD research.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/lncrna-cytor-promotes-lung-adenocarcinoma-gemcitabine-resistance-and-epithelial-mesenchymal-transition/333270/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/lncrna-cytor-promotes-lung-adenocarcinoma-gemcitabine-resistance-and-epithelial-mesenchymal-transition/333270.png","ImageObject",300,407,{"name":92,"@type":93},"Lucas Martin","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-07","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What does the study focus on regarding lung adenocarcinoma (LUAD)?","Question",{"text":112,"@type":113},"The study investigates how lncRNA CYTOR is involved in LUAD progression, specifically its role in gemcitabine resistance and epithelial-mesenchymal transition (EMT).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did the authors assess CYTOR expression and its relation to prognosis?",{"text":117,"@type":113},"CYTOR expression and clinical associations were analyzed using quantitative RT-PCR and Kaplan-Meier survival analysis.",{"name":119,"@type":110,"acceptedAnswer":120},"What mechanism explains how CYTOR promotes gemcitabine resistance?",{"text":121,"@type":113},"CYTOR functions as a competitive endogenous RNA that sponges miR-125a-5p, weakens the antitumor effects of miR-125a-5p, and increases ANLN and RRM2 expression, supporting EMT and drug resistance.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},333270,1790044077,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Original Article  \nlncRNA CYTOR promotes lung adenocarcinoma gemcitabine resistance and epithelial-mesenchymal transition by sponging miR-125a-5p and upregulating ANLN and RRM2 Qijun Cao 1,2,†, Haixia Wang3,†, Jialong Zhu 1,†, Chen Qi4, *, Hairong Huang4, *, and  \nXiaoyuan Chu 1, *  \n1 Department of Medical Oncology, Jinling Hospital, the First School of Clinical Medicine, Southern Medical University, Nanjing 210016, China, 2 Department of Medical Oncology, Cixi Hospital Affiliated to Wenzhou Medical University, Ningbo 315300, China, 3 Department of Cardiovascular Medicine, Cixi Hospital Affiliated to Wenzhou Medical University, Ningbo 315300, China, and 4Department of Cardiothoracic  \nSurgery, Jinling Hospital, Medical School of Nanjing University, Nanjing 210093, China †These authors contributed equally to this work.  \n*Correspondence address. Tel: +86-25-80864770; E-mail: [chuxiaoyuan000@163.com](chuxiaoyuan000@163.com) (X. C. ) / E-mail: [huang_hai_rong_01@aliyun.com](huang_hai_rong_01@aliyun.com) (H. H. ) / E-mail: [qichen007@yeah.net](qichen007@yeah.net) (C. Q. )  \nReceived 16 March 2023 Accepted 15 September 2023  \nAbstract  \nLung adenocarcinoma (LUAD) is one of the most aggressive types of lung cancer. The prognosis of LUAD patients remains poor, and the overall efficacy of gemcitabine-based chemotherapy is still unsatisfactory. Long noncoding RNAs (lncRNAs) play important roles in several cancer types by interacting with multiple proteins, RNA, and DNA. However, the relationship between lncRNA dysregulation and gemcitabine resistance in LUAD has not been fully elucidated. In this study, lncRNA CYTOR expression and its association with the prognosis of LUAD patients are assessed by quantitative RT-PCR and Kaplan-Meier survival analysis. In vitro and in vivo functional studies are conducted to evaluate the biological functions of CYTOR in LUAD. The underlying mechanism regarding the tumorpromoting effects of CYTOR is explored using RNA immunoprecipitation, biotin-labelled RNA pulldown, luciferase reporter assays, and western blot analysis. We identify that CYTOR is an oncogenic lncRNA and is apparently upregulated in LUAD by analysing TCGA-LUAD data. High CYTOR expression is a poor prognostic factor for LUAD. Functional studies reveal that CYTOR confers LUAD cells with stronger resistance to gemcitabine treatment and upregulates the expression levels of epithelial-mesenchymal transition (EMT)-related proteins. Mechanically, CYTOR acts as a competitive endogenous RNA (ceRNA) to absorb miR-125a-5p, weakens the antitumor function of miR-125a-5p, and ultimately upregulates ANLN and RRM2 expressions. Taken together, this study explains the mechanism of lncRNA in the gemcitabine resistance of LUAD and formulates a theoretical framework for the in depth study of LUAD.  \nKey words CYTOR, lung adenocarcinoma, chemoresistance, miR-125a-5p  \nIntroduction  \nLung adenocarcinoma (LUAD) is usually derived from the bronchial epithelium, with some cases originated from the large bronchial mucous glands. LUAD is more likely to occur in women, Asians, and nonsmokers, and the incidence of LUAD has been increasing in recent years [1,2] . Although LUAD typically grows slowly and develops small masses, it easily metastasizes at an early stage and  \ndevelops resistance to conventional treatment, such as radiotherapy and chemotherapy, which results in poor clinical efficacy and poor prognosis for LUAD patients [3,4] . For LUAD patients with locally advanced or metastatic disease, gemcitabine and gemcitabinebased strategies are the standard chemotherapies [5,6] . Gemcitabine (dFdC) is a pyrimidine antimetabolite that is metabolized into active nucleoside diphosphate (dFdCDP) and nucleoside  \n© The Author(s) 2023. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License ([https://](https://)[ ](https://)[creativecommons.org/licenses/by-nc-nd/4.0/).](creativecommons.org/licenses/","cbCaivsXbuniqwVx","https://ap.wps.com/l/cbCaivsXbuniqwVx","pdf",3840535,13,"English","# Abstract\n# Introduction\n## Background of LUAD and treatment challenges\n## Rationale for studying lncRNAs and CYTOR\n# Methods (implied by abstract)\n## Expression and survival analyses\n## Functional assays in vitro and in vivo\n## Mechanistic experiments (RNA/EMT pathway)","[{\"question\":\"What does the study focus on regarding lung adenocarcinoma (LUAD)?\",\"answer\":\"The study investigates how lncRNA CYTOR is involved in LUAD progression, specifically its role in gemcitabine resistance and epithelial-mesenchymal transition (EMT).\"},{\"question\":\"How did the authors assess CYTOR expression and its relation to prognosis?\",\"answer\":\"CYTOR expression and clinical associations were analyzed using quantitative RT-PCR and Kaplan-Meier survival analysis.\"},{\"question\":\"What mechanism explains how CYTOR promotes gemcitabine resistance?\",\"answer\":\"CYTOR functions as a competitive endogenous RNA that sponges miR-125a-5p, weakens the antitumor effects of miR-125a-5p, and increases ANLN and RRM2 expression, supporting EMT and drug resistance.\"}]","lncRNA CYTOR promotes lung adenocarcinoma gemcitabine resistance and epithelial-mesenchymal transition | PDF",1790001736,33]